{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:39:08Z","timestamp":1790872748850,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.leukres.2024.107467","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T09:52:49Z","timestamp":1709113969000},"page":"107467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia"],"prefix":"10.1016","volume":"139","author":[{"given":"Garrett","family":"Bourne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Diebold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Espinoza-Gutarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Al-Kadhimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimo","family":"Bachiashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravanti","family":"Rangaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.leukres.2024.107467_bib1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ajh.23795","article-title":"Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia","volume":"89","author":"Borthakur","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107467_bib2","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1002\/cncr.23927","article-title":"Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival","volume":"113","author":"Borthakur","year":"2008","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.leukres.2024.107467_bib3","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","article-title":"Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a cancer and leukemia group B study","volume":"23","author":"Marcucci","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107467_bib4","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"Borthakur","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2024.107467_bib5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1158\/2159-8290.CD-15-0298","article-title":"Mass cytometric functional profiling of acute myeloid leukemia defines cell-cycle and immunophenotypic properties that correlate with known responses to therapy","volume":"5","author":"Behbehani","year":"2015","journal-title":"Cancer Discov."},{"issue":"9825","key":"10.1016\/j.leukres.2024.107467_bib6","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.leukres.2024.107467_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2024.107467_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.leukres.2024.107467_bib9","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2024.107467_bib10","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2024.107467_bib11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2024.107467_bib12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41375-022-01738-3","article-title":"Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients","volume":"37","author":"Boyiadzis","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2024.107467_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clml.2015.07.646","article-title":"How center volumes affect early outcomes in acute myeloid leukemia","volume":"15","author":"Hahn","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2024.107467_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated versus single dose gemtuzumab ozogamicin with determinants of benefit in older AML: UK NCRI AML18 trial","author":"Freeman","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2024.107467_bib15","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","article-title":"Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107467_bib16","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.leukres.2024.107467_bib17","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107467_bib18","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.leukres.2024.107467_bib19","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2024.107467_bib20","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2024.107467_bib21","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group B study","volume":"24","author":"Paschka","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107467_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-021-00503-6","article-title":"Core binding factor acute myelogenous leukemia-2021 treatment algorithm","volume":"11","author":"Borthakur","year":"2021","journal-title":"Blood Cancer J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262400033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262400033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T19:46:27Z","timestamp":1711136787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262400033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":22,"alternative-id":["S014521262400033X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107467","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107467"}}